Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 (everolimus) vs placebo in advanced pancreatic neuroendocrine tumors
2006-006819-75Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in islet cell tumor and pancreatic carcinoid tumor comparing Everolimus 10 mg/day plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Progression-free survival. Started Jun 2007; status: completed.
02
Drugs
everolimus
03
Conditions
islet cell tumorpancreatic carcinoid tumor
Beyond the preview
Go deeper on 2006-006819-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006819-75.